The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Rationale & results of a pilot study of elotuzumab in myelofibrosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the rationale for using elotuzumab in myelofibrosis (MF), commenting on the results of a study that showed that the drug was active in a small cohort of patients and produced anemia, symptom, bone marrow fibrosis, and platelet responses. Dr Bose explains that this drug may potentially be used in combination with other agents in the future. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
